ArticleBMC infectious diseases2025
Risk factors for bloodstream infection and predictors of prognosis in rectal carriers of carbapenem-resistant Klebsiella pneumoniae.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Impact of loading dose β-lactam therapy on outcomes of KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients: a real world study.The Journal of antimicrobial chemotherapy · 2026Article
- Clinical characteristics and risk factor analysis of multidrug-resistant bacterial bloodstream infections in adult acute leukemia patients.Frontiers in microbiology · 2026Article
- Clinical Epidemiological Analysis of the Genotypic Spectrum and Mortality Risk in Carbapenem-ResistantThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe mortality rate of secondary bloodstream infection (BSI) derived from the intestinal colonization of carbapenem-resistant Klebsiella pneumoniae (CRKP) is extremely high. This investigation aimed at clarifying the risk factors and prognosis of BSIs resulting from the initial colonisation of CRKP.
methodsIn this retrospective, cross-sectional study, we analyzed the clinical data of 167 patients with CRKP colonization who received active screening during hospitalization at Zhejiang Provincial People’s Hospital from January 2019 to December 2021. The cohort consisted of 34 patients with BSI (CRKP BSI group) and 133 patients without BSI (No-BSI CRKP group).Logistic regression was employed to identify risk factors for progression from CRKP intestinal colonization to secondary BSI.Cox proportional hazards regression models were used to analyze independent risk factors for 28-day crude mortality from CRKP BSI.
resultsMultivariable analysis revealed that previous use of carbapenems (odds ratio [OR]:4.14, 95% confidence interval [CI]: 1.07–16.0, P = 0.040), corticosteroid use (OR: 3.18, 95% CI: 1.16–8.74, P = 0.025), and agranulocytosis (OR: 7.54, 95% CI: 2.09–27.2; P = 0.002) were independent risk factors for BSI in patients with CRKP rectal colonization. The overall mortality rate for CRKP infection was 20.4% (34/167), and the crude 28-day mortality rate for CRKP BSI was 44.1% (15/34), which was independently associated with hematologic neoplasms (P < 0.001). Among the 11 genotypically evaluated CRKP strains, 10 harbored the blaKPC−2 gene.
conclusionsNeutrophil deficiency, previous use of carbapenems, and corticosteroid use are risk factors for BSI following CRKP colonization. Patients with hematologic neoplasms associated with CRKP infection are at high risk of death. Patients with clinical risk factors should be identified early, and targeted intervention measures should be taken to optimize antibiotic use and reduce the risk of subsequent BSI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.